Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NGLY1 | Q96IV0 | 1/20 | 0.33 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | GANAB | Q14697 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1404005 | 1.00 | SLC18A3 (0.38) | SLC18A3PKMGAAMEN1CYP1A2 | |
| SCHEMBL5398154 | 0.72 | SLC18A3 (0.41) | SLC18A3PKMGAAMEN1CYP1A2 | |
| SCHEMBL27816064 | 0.72 | SLC18A3 (0.41) | SLC18A3PKMGAAMEN1CYP1A2 | |
| SCHEMBL1404038 | 0.70 | SLC18A3 (0.44) | SLC18A3PKMGAAMEN1CYP1A2 | |
| SCHEMBL1845216 | 0.68 | SLC18A3 (0.38) | SLC18A3PKMGAAMEN1CYP1A2 | |
| SCHEMBL3391750 | 0.68 | SLC18A3 (0.38) | SLC18A3PKMGAAMEN1CYP1A2 | |
| SCHEMBL2801018 | 0.68 | SLC18A3 (0.38) | SLC18A3PKMGAAMEN1CYP1A2 | |
| SCHEMBL2300746 | 0.65 | — | — | |
| SCHEMBL8592641 | 0.64 | SLC18A3 (0.39) | SLC18A3PKMGAAMEN1CYP1A2 | |
| SCHEMBL1862738 | 0.64 | CHRNA7 (0.42) | SLC18A3PKMGAAMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2291374-B1 | PROCESS FOR PREPARATION OF SOLIFENACIN AND/OR THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF OF HIGH PHARMACEUTICAL PURITY | ZAKLADY FARM POLPHARMA SA (PL) | 2015-04-15 | — | — | EP | claimed |
| US-8436182-B2 | Process for preparation of solifenacin and/or the pharmaceutically acceptable salts thereof of high pharmaceutical purity | ZAKLADY FARMACEUTYCZNE POLPHARMA SA (PL) | 2013-05-07 | — | — | US | claimed |
| US-20110065922-A1 | Process for Preparation Of Solifenacin and/or the Pharmaceutically Acceptable Salts Thereof of High Pharmaceutical Purity | ZAKLADY FARMACEUTYCZNE POLPHARMA SA (PL) | 2011-03-17 | — | — | US | claimed |
| EP-2291374-B1 | PROCESS FOR PREPARATION OF SOLIFENACIN AND/OR THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF OF HIGH PHARMACEUTICAL PURITY | ZAKLADY FARM POLPHARMA SA (PL) | 2015-04-15 | — | — | EP | disclosed |
| US-8436182-B2 | Process for preparation of solifenacin and/or the pharmaceutically acceptable salts thereof of high pharmaceutical purity | ZAKLADY FARMACEUTYCZNE POLPHARMA SA (PL) | 2013-05-07 | — | — | US | disclosed |
| US-20110065922-A1 | Process for Preparation Of Solifenacin and/or the Pharmaceutically Acceptable Salts Thereof of High Pharmaceutical Purity | ZAKLADY FARMACEUTYCZNE POLPHARMA SA (PL) | 2011-03-17 | — | — | US | disclosed |